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Delirium is a psychiatric disorder that is well known for being a clinical 
challenge due to its complex pathophysiology and the wide range of risk 
factors associated with it. Up to this date, no medical agent is approved by 
the Food and Drug Administration (FDA) for the treatment of delirium; 
despite the fact that, a number of clinical guidelines and protocols have 
recommended the use of some drugs in the management of delirium. Delirium 
risk factors; predisposing, hospital and acute underlying disease factors, are 
considered critical points in understanding delirium mechanism. Furthermore, 
several pathophysiological hypotheses; neurotransmitters imbalance 
hypothesis, inflammatory hypothesis and structural defects hypothesis, were 
introduced to explain delirium pathogenesis. Nevertheless, the current 
evidence is mainly based on and validates the neurotransmitters imbalance 
theory, since neurotransmitters form the molecular basis of the central nervous 
system and can be affected by any change occurs in the brain normal 
conditions. Moreover, pharmacological options introduced as delirium 
therapies with relative efficacy are mainly based on the neurotransmitters 
imbalance theory. Ketanserin is a centrally acting antihypertensive agent that 
has been in the market for over 30 years from now; thus, safety profile is well 
established. Ketanserin special and unique mechanism of action by inhibiting a 
wide range of central nervous system receptors; serotonergic (5-HT1D, 5-
HT2B, 5-HT2C, 5-HT6), dopaminergic (D1, D2) and adrenergic (α1, α2) 
receptors, theoretically seems to match with the pathophysiological hypothesis 
of neurotransmitters imbalance. Moreover, ketanserin might also serve as an 
empirical therapy for delirium, when the cause of delirium; other than the 
underlying medical condition, is not determined and an immediate 
intervention is needed. As it antagonizes almost all the receptors thought to 
be associated with delirium. Nevertheless, up to this point, it is still a 
theoretical assumption about the potential role of ketanserin as a 
pharmacological option in delirium management that needs further 
investigations to confirm its efficacy.                  
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Introduction 
 
Delirium is defined as a transient state of confusion that impairs individuals’ 
normal cognitive functions [1]. It could be classified as a syndrome rather than a 
mental disorder, as it is characterized by a number of defined signs and 
symptoms associated with its occurrence. For instance, hyper/hypoactivity, 
inability to focus, illusions, sleep disturbances, perceptual impairments and other 
cognitive defects [2]. Delirium episodes usually occur due to an organic cause that 
changes the brain normal conditions, such as an underlying medical condition or 
a drug-induced case [3]. Therefore, treating the primary cause is the first step in 
delirium management [4]. Nevertheless, delirium symptoms and diagnosis are 
frequently confused with other mental disorders [5]; thus, close monitoring and 
assessment should be undertaken to avoid any possible misdiagnosis.  
Elderly hospitalized patients are identified to be at a higher risk of developing 
delirium episodes [6]. Hospital procedures and hospital environment are known 
add risk factors other than the underlying condition; for example, ICU (Intensive 
Care Unit) patients on mechanical ventilation were observed to be 2 – 3 times 
more likely to develop delirium in the ICU compared to non-mechanically 
ventilated patients [7]. Moreover, delirium episodes could increase the 
hospitalization period resulting in an increased treatment costs, long-term 
cognitive impairments and elevated mortality rates within the first year after 
discharge [8]. Thus, delirium cases should be carefully handled in order to 
minimize its detrimental futuristic complications. 
Pharmacological options, which are the central core of any disease 
management protocol, are yet to be approved by the FDA for the treatment of 
delirium [9]. On the other hand, a number of guidelines have suggested the 
effectiveness and recommended the use of some medical agents, such as typical 
antipsychotics, atypical antipsychotics, dexmedetomidine and benzodiazepines 
[10]. Although these pharmacological options seem to be effective and relatively 
safe as reported by the clinical investigations [11], the pathophysiology of 
delirium is very complex and the disease molecular mechanism is not fully 
understood. Thus, more studies should be undertaken in order to approve the use 
of the current pharmacological therapies.  
Ketanserin is a centrally acting antihypertensive agent that was discovered in 
1980, which is clinically used in patients with hypertension; in addition to, its use 
in understanding the serotonin system in scientific research [12]. The theoretical 
assumption about ketanserin potential role in delirium treatment is mainly based 
on its unique mechanism of action that might fit with the introduced 
pathophysiological hypotheses of delirium. Therefore, the pathophysiological 
hypotheses and delirium risk factors would be explained in order to assess the 
relation between ketanserin and delirium mechanism. 
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Delirium risk factors 
 
The risk factors of delirium can be classified into three major categories; 
predisposing, hospital related and the underlying acute condition factors. 
Moreover, multiple risk factors could be added together and elevate the risk and 
severity of delirium, such as the case of hospitalized ICU patients who may have 
over ten different risk factors at the same time [13]. 
 
 
Predisposing factors (Baseline factors) 
Predisposing factors are commonly related to the individual’s normal life 
habits or medical history. These risk factors may include; patient’s age [14], 
smoking [15], alcohol consumption [16], history of depression [17], history of 
hypertension [18] and other factors related to genetic disposition, such as APOE-
4 (Apolipoprotein - 4) polymorphism [19]. However, those risk factors are critical 
and should be assessed and taken into consideration prior the start of the medical 
treatment or hospital admission in order to minimize the risk of developing 
delirium. 
 
Hospital related factors  
For patients who require hospitalization, risk factors are mainly related to the 
surrounding hospital environment. For example, physical restrain and patient 
immobility are suggested to increase delirium risk [20]. Moreover, sleep 
deprivation and sleep disturbances, which frequently occur in hospitalized 
patients, are major contributors in precipitating delirium [20]. 
 
Underlying acute condition risk factors 
The underlying acute condition is the main identified cause of delirium. 
However, many factors could be related to its severity and the type of medical 
intervention used. These factors might include; the use of mechanical ventilation, 
surgical operations, polypharmacy, metabolic disturbances, elevated levels of 
inflammatory biomarkers and sepsis development [21]. 
 
 
Delirium pathophysiology hypotheses 
 
A number of pathophysiological hypotheses were introduced in order to figure 
out delirium mechanism. The hypotheses are; neurotransmitters imbalance 
hypothesis, inflammatory hypothesis and structural defects hypothesis. These 
hypotheses are still theories that are yet to be approved; however, clinical trials 
to some extent have generated an evidence that suggests their viability in 
explaining delirium pathogenesis. 
 
Neurotransmitters imbalance hypothesis  
Neurotransmitters play a vital role in cell signaling that controls almost all 
physiological functions. Disturbance in the levels of neurotransmitters is thought 
to be one of the major contributors in delirium pathogenesis. Imbalanced levels 
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of; acetylcholine, dopamine, serotonin, GABA (Gamma Amino Butyric Acid) and 
glutamate, are suggested to participate in precipitating delirium.  
 
Acetylcholine  
Cholinergic deficiency theory is suggested to be strongly associated with 
delirium development. In which, studies have compared levels of acetylcholine 
with the incidence of delirium and found that delirium occurs more frequently in 
patients with low levels of acetylcholine [22]. Moreover, the reticular activating 
system in the central nervous system, which is responsible for maintaining the 
circadian rhythm (sleep cycle), is also suggested to have a role in reducing 
acetylcholine levels in the brain due to sleep disturbances [23]. Thus, explaining 
the increased delirium incidence in hospitalized patients who often have sleep 
issues.  
 
Dopamine   
Dopamine is another major neurotransmitter in the central nervous system. 
However, it is found to have an inverse relation with acetylcholine; in other 
words, patients with elevated levels of dopamine have lowered levels of 
acetylcholine and vice versa [24]. This could be due to the existence of dopamine 
receptors – D2 subtype near the cholinergic fibers in the brain cortex [25]. Thus, 
resulting in reducing acetylcholine synthesis and cholinergic deficiency. Moreover, 
increased levels of dopamine are associated with psychotic symptoms and blurred 
thinking, which are both signs of delirium [25].  
 
Serotonin  
Serotonin neurotransmitter synthesis is quite different from other 
neurotransmitters, as serotonin is mainly derived from the amino acid 
tryptophan, while the other majority of neurotransmitter are derived from 
tyrosine [26]. However, scientists have developed a measuring method 
tryptophan/LNAA (Large Neutral Amino Acids) ratio to measure serotonin 
levels, since tryptophan crosses the blood-brain barrier via the aid of specific 
transporters that usually competes with LNAA [26]. However, delirium incidence 
could be as a result of both increased and reduced levels of serotonin. For 
example, in the case of hepatic encephalopathy, which attenuates the blood-brain 
barrier, serotonin synthesis will increase; thus, developing psychotic symptoms 
and elevating the risk of developing serotonin syndrome [27]. On the other hand, 
reducing the blood-brain barrier permeability would result in reducing serotonin 
levels; for instance, delirium associated with patients receiving levodopa and in 
the case of alcohol withdrawal [26]. Moreover, disturbed levels of serotonin are 
suggested to lower cholinergic activity; in addition to, increased levels of 
serotonin are found to promote dopamine release [28]. 
 
Norepinephrine  
Norepinephrine is an adrenergic neurotransmitter that is identified to have 
various biological functions in the central nervous system; for instance, 
neuroplasticity, cell metabolism, regulation of cortical circuits and inflammation 
[29]. It has also found to play a role in attention, controlling the mood and 
anxiety, which is quite similar to dopamine [29]. Furthermore, in delirium 
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episodes increased levels of norepinephrine has two main related modes of action; 
increasing dopamine activity and lowering acetylcholine levels, which are both 
considered hallmarks of delirium pathophysiology [28].  
 
GABA and glutamate  
Despite the fact that glutamate is the precursor of GABA; nevertheless, they 
both identified to play totally different functions. In which, glutamate is the 
main excitatory neurotransmitter in the central nervous system, while GABA is 
the major inhibitory neurotransmitter [30]. Their mechanism in precipitating 
delirium is not fully understood; however, it is suggested to have a relation with 
cholinergic deficiency [28]. For example, low levels of GABA in the case of 
sedatives or hypnotics withdrawal are observed to induce delirium; thus, 
suggesting that lowered levels of GABA are associated with delirium 
development [31].  
 
 
Inflammatory hypothesis 
This theory suggests the involvement of a number of immune system 
components in delirium pathogenesis. In the case of hospitalized patients, there is 
a higher risk of acquiring an infection from the hospital environment, that may 
aggravate to a generalized infection [32]. A generalized infection exposes the 
human body to a massive amount of immune system components [32]. For 
instance, clinical studies have shown a link between increased levels of IL-6 
(Interleukin-6), IL-8 (Interlaken-8) and delirium in elderly individuals [33]. 
However, the exact mechanism by which they induce delirium is still unclear [33]. 
 
Structural defects hypothesis  
The structural defects and anatomical changes are major factors in the 
disruption of the central nervous system homeostasis. Therefore, it is believed to 
have a role in the pathogenesis of delirium. For example, patients with strokes 
have a higher risk of developing delirium [34]; moreover, COMT (catechol-O-
methyltransferase) gene polymorphism in alcohol withdrawal associated delirium 
[35]. Furthermore, blood-brain barrier defect is another vital player in exposing 
the central nervous system to a massive range of neurotoxins that would 
participate in delirium development [36]. Thus, identifying those structural 
defects might significantly reduce the occurrence of delirium. 
 
According to the three major previously mentioned pathophysiological 
theories of delirium, the neurotransmitters imbalance theory seems to be the 
most viable one. This assumption is made based on the fact that 
neurotransmitters are the smallest molecular level of any of the body systems; 
therefore, other theories regarding inflammation and structural defects may to 
some extent have an effect on the neurotransmitters of the central nervous 
system. Moreover, the current pharmacological options that follow the 
neurotransmitters theory seems to be effective and relatively safe. 
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Ketanserin potential role 
 
According to the early mentioned points, it could be suggested that targeting 
the neurotransmitters systems might have positive outcomes in treating delirium 
or preventing it in the first place, especially in the individuals who have multiple 
risk factors. There are few reasons based on a scientific evidence about the 
theoretical assumption made on the potential role of ketanserin in delirium. 
Firstly, ketanserin is already a drug in use in patients with hypertension for 
decades; therefore, it is an available pharmacological agent that already passed 
human safety assessments in clinical trials [37]. Moreover, there are no reported 
cases of increased delirium risk in patients receiving ketanserin compared to other 
centrally acting antihypertensive; for example, clonidine that is identified to be 
associated with increased risk of delirium [38]. 
Furthermore, the most vital point about ketanserin is its mechanism of action, 
which is characterized by a wide range of antagonistic activity towards many 
subtypes of central nervous system receptors. Ketanserin is found to have a high 
antagonistic activity on the serotonin receptor subtype 5HT2A and H1 histamine 
receptor [12]. Moreover, at lower affinity ketanserin is also found to antagonize; 
serotonin receptors subtypes (5-HT1D, 5-HT2B, 5-HT2C, 5-HT6), dopamine 
receptors (D1, D2) and adrenergic receptors (α1, α2) [12]. According to the 
neurotransmitters imbalance theory, it could be observed that there is a relation 
between the mechanism of action of ketanserin and delirium pathogenesis. As 
ketanserin could be able to lower levels of dopamine, serotonin and 
norepinephrine, in which their elevated levels are associated with precipitating 
delirium and psychotic symptoms [39]. Moreover, ketanserin could also indirectly 
increase acetylcholine due to the inhibition of its suppressors; dopamine, 
serotonin and norepinephrine [28]. Therefore, ketanserin unique mechanism of 
action theoretically matches the neurotransmitters imbalance theory of delirium.  
Regarding the ability of ketanserin to block a huge number of receptors, it 
could be argued that it may potentially increase unwanted adverse events. 
Nevertheless, clinical investigations made on various pharmacological agents have 
shown that these drugs are effective in treating delirium at low doses with 
minimal side effects [40]. For instance, a study on haloperidol, which is 
considered the current gold standard treatment of delirium by blocking the 
dopamine-D2 receptor, has shown a lowered risk of developing extrapyramidal 
side effects associated with the use of haloperidol [41]. In addition, delirium is an 
acute and transient disorder; in other words, the patient exposure to the 
treatment would be for a very short period of time (hours/days) [42]. Thus, the 
risk of the drug to be build up in the body would be reduced [41]. Lastly, 
ketanserin antagonizes all receptors that are thought to be associated with 
delirium; thus, it could serve as an empirical therapeutic agent in the case of the 
unknown cause of delirium episodes, whether it is due to an increase in serotonin, 
norepinephrine or dopamine levels.  
Ultimately, ketanserin appears to have a potential role in delirium 
management according to its mechanism of action and the disease pathogenesis. 
However, it should be pointed out that it is only theoretical assumptions based 
on the scientific evidence available about delirium and ketanserin. Therefore, 
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further clinical investigations are needed to confirm the efficacy and activity of 
ketanserin in the treatment process of delirium. 
 
 
Conclusion 
 
In conclusion, delirium is a serious medical issue that has massive negative 
complications that significantly lowers the patients’ quality of life. Individuals 
may enter the hospital for an acute medical issue and discharge with a lifetime 
cognitive impairments because of delirium. Thus, aiming to find and discover 
novel pharmacological options for the treatment of delirium is a current major 
trend that has been gaining momentum in the past years. According to the 
current pathophysiology of delirium, ketanserin mode of action could possibly 
benefit in delirium management. Furthermore, Ketanserin seems as a feasible, 
more practical and cost-effective option, since it has already been clinically tested 
and approved as an antihypertensive; hence, it has an established safety profile. 
Nevertheless, ketanserin has never been tested on delirium patients to assess its 
efficacy and it is still a theoretical assumption based on current literature 
evidence. Therefore, it is well recommended to undertake further investigations 
to examine its actual potential. 
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